Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSI-082 Monotherapy and Combined Therapy in Advanced or Metastatic Solid Tumors
NCT07086768Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BSI-082 in solid tumor (7 cohorts). Primary endpoint: Dose Limiting Toxicity at 42 days. Started Jan 2026; status: recruiting.
02
Drugs
BSI-082
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07086768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086768.